JP7301839B2 - Ｌｐａアンタゴニストとしてのピラゾールｎ－連結のカルバモイルシクロヘキシル酸 - Google Patents

Ｌｐａアンタゴニストとしてのピラゾールｎ－連結のカルバモイルシクロヘキシル酸 Download PDF

Info

Publication number
JP7301839B2
JP7301839B2 JP2020533674A JP2020533674A JP7301839B2 JP 7301839 B2 JP7301839 B2 JP 7301839B2 JP 2020533674 A JP2020533674 A JP 2020533674A JP 2020533674 A JP2020533674 A JP 2020533674A JP 7301839 B2 JP7301839 B2 JP 7301839B2
Authority
JP
Japan
Prior art keywords
methyl
oxy
amino
pyrazol
cyclohexane
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2020533674A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021507895A (ja
JPWO2019126085A5 (https=
JP2021507895A5 (https=
Inventor
ヤン・シ
ピーター・タイ・ワー・チェン
イン・ワン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bristol Myers Squibb Co
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of JP2021507895A publication Critical patent/JP2021507895A/ja
Publication of JPWO2019126085A5 publication Critical patent/JPWO2019126085A5/ja
Publication of JP2021507895A5 publication Critical patent/JP2021507895A5/ja
Application granted granted Critical
Publication of JP7301839B2 publication Critical patent/JP7301839B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pulmonology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
JP2020533674A 2017-12-19 2018-12-18 Ｌｐａアンタゴニストとしてのピラゾールｎ－連結のカルバモイルシクロヘキシル酸 Active JP7301839B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762607541P 2017-12-19 2017-12-19
US62/607,541 2017-12-19
PCT/US2018/066110 WO2019126085A1 (en) 2017-12-19 2018-12-18 Pyrazole n-linked carbamoyl cyclohexyl acids as lpa antagonists

Publications (4)

Publication Number Publication Date
JP2021507895A JP2021507895A (ja) 2021-02-25
JPWO2019126085A5 JPWO2019126085A5 (https=) 2022-02-01
JP2021507895A5 JP2021507895A5 (https=) 2022-02-01
JP7301839B2 true JP7301839B2 (ja) 2023-07-03

Family

ID=65003575

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020533674A Active JP7301839B2 (ja) 2017-12-19 2018-12-18 Ｌｐａアンタゴニストとしてのピラゾールｎ－連結のカルバモイルシクロヘキシル酸

Country Status (14)

Country Link
US (1) US11384067B2 (https=)
EP (1) EP3728216B1 (https=)
JP (1) JP7301839B2 (https=)
KR (1) KR102698386B1 (https=)
CN (1) CN111699180B (https=)
AU (1) AU2018388482A1 (https=)
BR (1) BR112020011953A2 (https=)
CA (1) CA3085347A1 (https=)
EA (1) EA202091500A1 (https=)
ES (1) ES2962367T3 (https=)
IL (1) IL275361A (https=)
MX (1) MX2020005874A (https=)
SG (1) SG11202005701VA (https=)
WO (1) WO2019126085A1 (https=)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR108838A1 (es) 2016-06-21 2018-10-03 Bristol Myers Squibb Co Ácidos de carbamoiloximetil triazol ciclohexilo como antagonistas de lpa
EP4011875A1 (en) 2017-12-19 2022-06-15 Bristol-Myers Squibb Company Triazole n-linked carbamoyl cyclohexyl acids as lpa antagonists
US11447475B2 (en) * 2017-12-19 2022-09-20 Bristol-Myers Squibb Company Isoxazole N-linked carbamoyl cyclohexyl acids as LPA antagonists
KR102788997B1 (ko) 2018-09-18 2025-03-28 브리스톨-마이어스 스큅 컴퍼니 Lpa 길항제로서의 옥사비시클로 산
ES2946657T3 (es) 2018-09-18 2023-07-24 Bristol Myers Squibb Co Acidos ciclopentílicos como antagonistas de LPA
CN111434655A (zh) * 2019-01-15 2020-07-21 武汉朗来科技发展有限公司 溶血磷脂酸受体拮抗剂及其制备方法
AU2020384883B2 (en) 2019-11-15 2023-11-16 Gilead Sciences, Inc. Triazole carbamate pyridyl sulfonamides as LPA receptor antagonists and uses thereof
TWI843503B (zh) 2020-06-03 2024-05-21 美商基利科學股份有限公司 Lpa受體拮抗劑及其用途
CN115867556B (zh) 2020-06-03 2025-05-06 吉利德科学公司 Lpa受体拮抗剂及其用途
CN114456157A (zh) * 2020-11-10 2022-05-10 武汉人福创新药物研发中心有限公司 氮取代氨基碳酸酯噻吩类化合物及其用途
WO2022174882A1 (en) * 2021-02-16 2022-08-25 Chiesi Farmaceutici S.P.A. 5-membered heterocyclyl carbamate derivatives as dual lpa receptor 1 and lpa receptor 2 inhibitors
TWI853704B (zh) 2021-05-11 2024-08-21 美商基利科學股份有限公司 Lpa受體拮抗劑及其用途
KR20240007233A (ko) 2021-05-13 2024-01-16 길리애드 사이언시즈, 인코포레이티드 Lpa 수용체 길항제 및 이의 용도
WO2023107938A1 (en) 2021-12-08 2023-06-15 Gilead Sciences, Inc. Lpa receptor antagonists and uses thereof
AR128613A1 (es) 2022-02-25 2024-05-29 Lhotse Bio Inc Compuestos y composiciones para el tratamiento de afecciones asociadas con la actividad del receptor de lpa
CN121773091A (zh) * 2023-09-08 2026-03-31 西藏海思科制药有限公司 杂芳环衍生物的lpar1拮抗剂及其用途
CN117024409A (zh) * 2023-10-10 2023-11-10 药康众拓(北京)医药科技有限公司 氘代lpa1抑制剂化合物及其用途
WO2026061483A1 (zh) * 2024-09-19 2026-03-26 西藏海思科制药有限公司 一种lpar1拮抗剂及其用途

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050070589A1 (en) 2003-09-02 2005-03-31 Khehyong Ngu Pyrazolyl inhibitors of 15- lipoxygenase
JP2015520201A (ja) 2012-06-20 2015-07-16 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ Ｌｐａｒ拮抗薬としての置換ピラゾール化合物
JP2016515536A (ja) 2013-03-15 2016-05-30 エピゲン バイオサイエンシズ, インコーポレイテッドEpigen Biosciences, Inc. 疾患の治療に有用な複素環化合物
JP2019518766A (ja) 2016-06-21 2019-07-04 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ Ｌｐａアンタゴニストとしてのカルバモイルオキシメチルトリアゾールシクロヘキシル酸
JP2021507897A (ja) 2017-12-19 2021-02-25 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ Ｌｐａアンタゴニストとしてのピラゾールｏ−架橋カルバモイルシクロヘキシル酸
JP2021507899A (ja) 2017-12-19 2021-02-25 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ Ｌｐａアンタゴニストとしてのイソキサゾールｏ−架橋カルバモイルシクロヘキシル酸
JP2021507898A (ja) 2017-12-19 2021-02-25 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ Ｌｐａアンタゴニストとしてのシクロヘキシル酸ピラゾールアゾール
JP2021508686A (ja) 2017-12-19 2021-03-11 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ Ｌｐａアンタゴニストとしてのトリアゾールｎ結合カルバモイルシクロヘキシル酸

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002062389A1 (en) 2001-02-08 2002-08-15 Ono Pharmaceutical Co., Ltd. Remedies for urinary diseases comprising lpa receptor controlling agents
DE102004038403B4 (de) 2004-08-07 2006-08-31 Sanofi-Aventis Deutschland Gmbh Verfahren zur Herstellung der enantiomeren Formen von cis-konfigurierten 3-Hydroxycyclohexancarbonsäure-Derivaten
WO2011017350A2 (en) 2009-08-04 2011-02-10 Amira Pharmaceuticals, Inc. Compounds as lysophosphatidic acid receptor antagonists
GB2474748B (en) 2009-10-01 2011-10-12 Amira Pharmaceuticals Inc Polycyclic compounds as lysophosphatidic acid receptor antagonists
GB2474120B (en) 2009-10-01 2011-12-21 Amira Pharmaceuticals Inc Compounds as Lysophosphatidic acid receptor antagonists
EA201390821A1 (ru) 2010-12-07 2013-10-30 Амира Фармасьютикалс, Инк. Антагонисты рецепторов лизофосфатидной кислоты и их применение
US8785442B2 (en) 2011-01-30 2014-07-22 Curegenix, Inc. Compound as antagonist of lysophosphatidic acid receptor, composition, and use thereof
WO2012138648A1 (en) 2011-04-06 2012-10-11 Irm Llc Compositions and methods for modulating lpa receptors
WO2013070879A1 (en) 2011-11-10 2013-05-16 Bristol-Myers Squibb Company Methods for treating spinal cord injury with lpa receptor antagonists
US20140329871A1 (en) 2011-12-04 2014-11-06 Angion Biomedica Corp. Small molecule anti-fibrotic compounds and uses thereof
SG11201407228PA (en) 2012-06-20 2014-12-30 Hoffmann La Roche N-aryltriazole compounds as lpar antagonists
UA109868C2 (ru) 2012-06-20 2015-10-12 Ф. Хоффманн-Ля Рош Аг Соединения n-алкилтриазола как антагонисты лизофосфатидной кислоты (lpar)
US20170283400A1 (en) * 2014-09-17 2017-10-05 Epizyme, Inc. Arginine methyltransferase inhibitors and uses thereof

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050070589A1 (en) 2003-09-02 2005-03-31 Khehyong Ngu Pyrazolyl inhibitors of 15- lipoxygenase
JP2015520201A (ja) 2012-06-20 2015-07-16 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ Ｌｐａｒ拮抗薬としての置換ピラゾール化合物
JP2016515536A (ja) 2013-03-15 2016-05-30 エピゲン バイオサイエンシズ, インコーポレイテッドEpigen Biosciences, Inc. 疾患の治療に有用な複素環化合物
JP2019518766A (ja) 2016-06-21 2019-07-04 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ Ｌｐａアンタゴニストとしてのカルバモイルオキシメチルトリアゾールシクロヘキシル酸
JP2021507897A (ja) 2017-12-19 2021-02-25 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ Ｌｐａアンタゴニストとしてのピラゾールｏ−架橋カルバモイルシクロヘキシル酸
JP2021507899A (ja) 2017-12-19 2021-02-25 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ Ｌｐａアンタゴニストとしてのイソキサゾールｏ−架橋カルバモイルシクロヘキシル酸
JP2021507898A (ja) 2017-12-19 2021-02-25 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ Ｌｐａアンタゴニストとしてのシクロヘキシル酸ピラゾールアゾール
JP2021508686A (ja) 2017-12-19 2021-03-11 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ Ｌｐａアンタゴニストとしてのトリアゾールｎ結合カルバモイルシクロヘキシル酸

Also Published As

Publication number Publication date
WO2019126085A1 (en) 2019-06-27
EP3728216B1 (en) 2023-09-06
EA202091500A1 (ru) 2020-09-14
KR20200100712A (ko) 2020-08-26
BR112020011953A2 (pt) 2020-11-17
KR102698386B1 (ko) 2024-08-22
EP3728216A1 (en) 2020-10-28
ES2962367T3 (es) 2024-03-18
CA3085347A1 (en) 2019-06-27
MX2020005874A (es) 2020-08-13
JP2021507895A (ja) 2021-02-25
US20210087173A1 (en) 2021-03-25
IL275361A (en) 2020-07-30
AU2018388482A1 (en) 2020-07-30
CN111699180A (zh) 2020-09-22
US11384067B2 (en) 2022-07-12
CN111699180B (zh) 2024-11-29
SG11202005701VA (en) 2020-07-29

Similar Documents

Publication Publication Date Title
JP7301839B2 (ja) Ｌｐａアンタゴニストとしてのピラゾールｎ－連結のカルバモイルシクロヘキシル酸
JP7202383B2 (ja) Ｌｐａアンタゴニストとしてのピラゾールｏ－架橋カルバモイルシクロヘキシル酸
JP7301840B2 (ja) Ｌｐａアンタゴニストとしてのイソキサゾールｎ結合カルバモイルシクロヘキシル酸
JP7256807B2 (ja) Ｌｐａアンタゴニストとしてのシクロヘキシル酸イソキサゾールアゾール
JP7274486B2 (ja) Ｌｐａアンタゴニストとしてのトリアゾールｎ結合カルバモイルシクロヘキシル酸
JP7526096B2 (ja) Ｌｐａアンタゴニストとしてのシクロヘキシル酸イソキサゾールアジン
JP7427658B2 (ja) Ｌｐａアンタゴニストとしてのシクロペンチル酸
JP7299892B2 (ja) Ｌｐａアンタゴニストとしてのシクロヘキシル酸ピラゾールアジン
JP7208240B2 (ja) Ｌｐａアンタゴニストとしてのシクロヘキシル酸トリアゾールアジン
JP7212047B2 (ja) Ｌｐａアンタゴニストとしてのシクロヘキシル酸ピラゾールアゾール
JP7369125B2 (ja) Ｌｐａアンタゴニストとしてのイソキサゾールｏ－架橋カルバモイルシクロヘキシル酸
JP7280881B2 (ja) Ｌｐａアンタゴニストとしてのシクロヘキシル酸トリアゾールアゾール
JP7465899B2 (ja) Ｌｐａアンタゴニストとしてのシクロブチルカルボン酸
JP7429224B2 (ja) Ｌｐａアンタゴニストとしてのシクロヘプチル酸
JP7412424B2 (ja) Ｌｐａアンタゴニストとしてのオキサビシクロ酸
JP7422788B2 (ja) Ｌｐａアンタゴニストとしてのイソキサゾールカルボン酸
JP2022536858A (ja) Ｌｐａアンタゴニストとしてのトリアゾールカルボン酸

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20211217

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220124

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20221110

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20221213

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230313

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20230613

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20230621

R150 Certificate of patent or registration of utility model

Ref document number: 7301839

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150